Hydronidone not checked
Beijing Continent Pharmaceutical Co, Ltd. · F351
FollowEvery change as it happens, and a Monday email
Trials
3 active
13 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.”In the company’s words, NCT05905172 on ClinicalTrials.gov
- Tested for
- Liver Fibrosis (2 trials), Liver Fibrosis in Chronic Hepatitis B, Renal Insufficiency Chronic
- Main trialPhase 3
- “This study is a Phase IIIb extension trial following the "A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B". The main objective of this study is to evaluate the effectiveness and the safety of hydronidone capsules for long-term treatment of patients with chronic viral hepatitis B liver fibrosis.”In the company’s words, NCT05905172 on ClinicalTrials.gov
- Other names
- F351
Other drugs for Liver Fibrosis
- ElafibranorIpsen · Phase 3
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
Coming up3
- 1 DecPhase 1 trial completes · ClinicalTrials.gov
- 20 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07412236
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 20 Jun 2028 | Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis | |
| Phase 3Recruiting | 30 Dec 2028 | A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. | |
| Phase 1Recruiting | 1 Dec 2026 | A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency | |
| Phase 3Completed | 22 Oct 2024 | Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. | |
| Phase 3Completed | 28 Jul 2026 | A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis | |
| Phase 2Completed | 22 Jun 2026 | A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis | |
| Phase 2Completed | 27 Jul 2026 | A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis | |
| Phase 1Completed | 27 Nov 2019 | Study on Pharmacokinetics of Hydronidone | |
| Phase 1Completed | 9 Oct 2020 | Study on PK of Hydronidone in Patients and Special Population | |
| Phase 1Completed | 9 Feb 2026 | QTc Assessment in a Single-Dose Study of Hydronidone Capsules | |
| Phase 1Completed | 6 May 2026 | [¹⁴C] Hydronidone Mass Balance Study | |
| Phase 1Completed | 11 May 2026 | Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls | |
| Phase 1Completed | 28 May 2026 | The Phase Ⅰd Clinical Trial of Hydronidone Capsules |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026